Literature DB >> 26070111

Engineered bacteria as therapeutic agents.

Carlos Piñero-Lambea1, David Ruano-Gallego1, Luis Ángel Fernández2.   

Abstract

Although bacteria are generally regarded as the causative agents of infectious diseases, most bacteria inhabiting the human body are non-pathogenic and some of them can be turned, after proper engineering, into 'smart' living therapeutics of defined properties for the treatment of different illnesses. This review focuses on recent developments to engineer bacteria for the treatment of diverse human pathologies, including inflammatory bowel diseases, autoimmune disorders, cancer, metabolic diseases and obesity, as well as to combat bacterial and viral infections. We discuss significant advances provided by synthetic biology to fully reprogram bacteria as human therapeutics, including novel measures for strict biocontainment.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26070111     DOI: 10.1016/j.copbio.2015.05.004

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  33 in total

1.  Advances in bacterial cancer therapies using synthetic biology.

Authors:  Tiffany Chien; Anjali Doshi; Tal Danino
Journal:  Curr Opin Syst Biol       Date:  2017-05-23

Review 2.  Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.

Authors:  Wei Pan; Yongbo Kang
Journal:  Int Urol Nephrol       Date:  2017-08-28       Impact factor: 2.370

3.  Evolution of C-Terminal Modification Tolerance in Full-Length and Split T7 RNA Polymerase Biosensors.

Authors:  Jinyue Pu; Michael Disare; Bryan C Dickinson
Journal:  Chembiochem       Date:  2019-04-17       Impact factor: 3.164

4.  Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis.

Authors:  Xu Yan; Xin-Yi Liu; Dian Zhang; Yu-Dian Zhang; Zi-Hua Li; Xu Liu; Fuqing Wu; Guo-Qiang Chen
Journal:  Cell Mol Immunol       Date:  2021-09-03       Impact factor: 22.096

5.  Genome Engineering of the Fast-Growing Mycoplasma feriruminatoris toward a Live Vaccine Chassis.

Authors:  Vincent Talenton; Vincent Baby; Geraldine Gourgues; Charlotte Mouden; Stephane Claverol; Sanjay Vashee; Alain Blanchard; Fabien Labroussaa; Joerg Jores; Yonathan Arfi; Pascal Sirand-Pugnet; Carole Lartigue
Journal:  ACS Synth Biol       Date:  2022-05-05       Impact factor: 5.249

Review 6.  Gut microbiome in chronic kidney disease: challenges and opportunities.

Authors:  Anitha Nallu; Shailendra Sharma; Ali Ramezani; Jagadeesan Muralidharan; Dominic Raj
Journal:  Transl Res       Date:  2016-04-30       Impact factor: 7.012

Review 7.  Engineering the gut microbiota to treat chronic diseases.

Authors:  Noura S Dosoky; Linda S May-Zhang; Sean S Davies
Journal:  Appl Microbiol Biotechnol       Date:  2020-07-21       Impact factor: 4.813

Review 8.  Engineering cell-based therapies to interface robustly with host physiology.

Authors:  Kelly A Schwarz; Joshua N Leonard
Journal:  Adv Drug Deliv Rev       Date:  2016-06-03       Impact factor: 15.470

9.  Evaluation of Surface Modified Live Biotherapeutic Products for Oral Delivery.

Authors:  Ava M Vargason; Aaron C Anselmo
Journal:  ACS Biomater Sci Eng       Date:  2020-12-30

10.  Efficient markerless integration of genes in the chromosome of probiotic E. coli Nissle 1917 by bacterial conjugation.

Authors:  Elena M Seco; Luis Ángel Fernández
Journal:  Microb Biotechnol       Date:  2021-11-09       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.